Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Lactate stimulates CA IX expression in normoxic cancer cells.

Oncotarget

Panisova E, Kery M, Sedlakova O, Brisson L, Debreova M, Sboarina M, Sonveaux P, Pastorekova S, Svastova E.
PMID: 29100428
Oncotarget. 2017 Sep 12;8(44):77819-77835. doi: 10.18632/oncotarget.20836. eCollection 2017 Sep 29.

Besides hypoxia, other factors and molecules such as lactate, succinate, and reactive oxygen species activate transcription factor hypoxia-inducible factor-1 (HIF-1) even in normoxia. One of the main target gene products of HIF-1 is carbonic anhydrase IX (CA IX). CA...

Cite
Panisova E, Kery M, Sedlakova O, et al. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget. 2017;8(44):77819-77835doi: 10.18632/oncotarget.20836.
Panisova, E., Kery, M., Sedlakova, O., Brisson, L., Debreova, M., Sboarina, M., Sonveaux, P., Pastorekova, S., & Svastova, E. (2017). Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget, 8(44), 77819-77835. https://doi.org/10.18632/oncotarget.20836
Panisova, Elena, et al. "Lactate stimulates CA IX expression in normoxic cancer cells." Oncotarget vol. 8,44 (2017): 77819-77835. doi: https://doi.org/10.18632/oncotarget.20836
Panisova E, Kery M, Sedlakova O, Brisson L, Debreova M, Sboarina M, Sonveaux P, Pastorekova S, Svastova E. Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget. 2017 Sep 12;8(44):77819-77835. doi: 10.18632/oncotarget.20836. eCollection 2017 Sep 29. PMID: 29100428; PMCID: PMC5652817.
Copy Download .nbib Format: NLM
An outbreak of Norwalk like virus gastroenteritis in a nursing home in Rotterdam.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Ronveaux O, Vos D, Bosman A, Brandwijk K, Vinje J, Koopmans M, Reintjes R.
PMID: 12631859
Euro Surveill. 2000 May;5(5):54-57. doi: 10.2807/esm.05.05.00006-en.

Sixty-two per cent of elderly and disabled residents of a Dutch nursing home (74/120) and 32% of staff (33/102) became ill in an outbreak of Norwalk-like viral gastroenteritis. The outbreak spread from person to person was supported by temporal...

Cite
Ronveaux O, Vos D, Bosman A, et al. An outbreak of Norwalk like virus gastroenteritis in a nursing home in Rotterdam. Euro Surveill. 2000;5(5):54-57doi: 10.2807/esm.05.05.00006-en.
Ronveaux, O., Vos, D., Bosman, A., Brandwijk, K., Vinje, J., Koopmans, M., & Reintjes, R. (2000). An outbreak of Norwalk like virus gastroenteritis in a nursing home in Rotterdam. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 5(5), 54-57. https://doi.org/10.2807/esm.05.05.00006-en
Ronveaux, O, et al. "An outbreak of Norwalk like virus gastroenteritis in a nursing home in Rotterdam." Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin vol. 5,5 (2000): 54-57. doi: https://doi.org/10.2807/esm.05.05.00006-en
Ronveaux O, Vos D, Bosman A, Brandwijk K, Vinje J, Koopmans M, Reintjes R. An outbreak of Norwalk like virus gastroenteritis in a nursing home in Rotterdam. Euro Surveill. 2000 May;5(5):54-57. doi: 10.2807/esm.05.05.00006-en. PMID: 12631859.
Copy Download .nbib Format: NLM
Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Ronveaux O, Bosman A, Reintjes R, Conyn-Van Spaendonck MA.
PMID: 12631924
Euro Surveill. 1998 Dec;3(12):122-124. doi: 10.2807/esm.03.12.00113-en.

The European Advisory Group on Immunisation has recommended that measles should be eliminated from Europe by the year 2007, a target accepted by National Immunisation Programme Managers for the World Health Organization (WHO) European Region countries. I

Cite
Ronveaux O, Bosman A, Reintjes R, et al. Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998. Euro Surveill. 1998;3(12):122-124doi: 10.2807/esm.03.12.00113-en.
Ronveaux, O., Bosman, A., Reintjes, R., & Conyn-Van Spaendonck, M. A. (1998). Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 3(12), 122-124. https://doi.org/10.2807/esm.03.12.00113-en
Ronveaux, O, et al. "Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998." Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin vol. 3,12 (1998): 122-124. doi: https://doi.org/10.2807/esm.03.12.00113-en
Ronveaux O, Bosman A, Reintjes R, Conyn-Van Spaendonck MA. Descriptive epidemiology of exanthems in the Rotterdam region January 1997 to June 1998. Euro Surveill. 1998 Dec;3(12):122-124. doi: 10.2807/esm.03.12.00113-en. PMID: 12631924.
Copy Download .nbib Format: NLM
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Frontiers in pharmacology

Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P.
PMID: 21904528
Front Pharmacol. 2011 Aug 25;2:49. doi: 10.3389/fphar.2011.00049. eCollection 2011.

CANCER IS A METABOLIC DISEASE AND THE SOLUTION OF TWO METABOLIC EQUATIONS: to produce energy with limited resources and to fulfill the biosynthetic needs of proliferating cells. Both equations are solved when glycolysis is uncoupled from oxidative phosphorylation in...

Cite
Porporato PE, Dhup S, Dadhich RK, et al. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011;2:49doi: 10.3389/fphar.2011.00049.
Porporato, P. E., Dhup, S., Dadhich, R. K., Copetti, T., & Sonveaux, P. (2011). Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Frontiers in pharmacology, 249. https://doi.org/10.3389/fphar.2011.00049
Porporato, Paolo E, et al. "Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review." Frontiers in pharmacology vol. 2 (2011): 49. doi: https://doi.org/10.3389/fphar.2011.00049
Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011 Aug 25;2:49. doi: 10.3389/fphar.2011.00049. eCollection 2011. PMID: 21904528; PMCID: PMC3161244.
Copy Download .nbib Format: NLM
Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells.

American journal of cancer research

Chano T, Avnet S, Kusuzaki K, Bonuccelli G, Sonveaux P, Rotili D, Mai A, Baldini N.
PMID: 27186436
Am J Cancer Res. 2016 Mar 15;6(4):859-75. eCollection 2016.

The glycolytic-based metabolism of cancers promotes an acidic microenvironment that is responsible for increased aggressiveness. However, the effects of acidosis on tumour metabolism have been almost unexplored. By using capillary electrophoresis with time-of-flight mass spectrometry, we observed a significant...

Cite
Chano T, Avnet S, Kusuzaki K, et al. Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. Am J Cancer Res. 2016;6(4):859-75
Chano, T., Avnet, S., Kusuzaki, K., Bonuccelli, G., Sonveaux, P., Rotili, D., Mai, A., & Baldini, N. (2016). Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. American journal of cancer research, 6(4), 859-75.
Chano, Tokuhiro, et al. "Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells." American journal of cancer research vol. 6,4 (2016): 859-75.
Chano T, Avnet S, Kusuzaki K, Bonuccelli G, Sonveaux P, Rotili D, Mai A, Baldini N. Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. Am J Cancer Res. 2016 Mar 15;6(4):859-75. eCollection 2016. PMID: 27186436; PMCID: PMC4859889.
Copy Download .nbib Format: NLM
An outbreak of legionnaire s disease among visitors to a fair in Belgium, 1999.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

De Schrijver K, Van Bouwel E, Mortelmans L, Van Rossom P, De Beukelaer T, Vael C, Dirven K, Goossens H, Leven M, Ronveaux O.
PMID: 12631961
Euro Surveill. 2000 Nov;5(11):115-119. doi: 10.2807/esm.05.11.00007-en.

Ninety-three cases of legionnaires disease (43 confirmed, 12 presumptive, and 38 possible/ clinical) were identified in an outbreak associated with a trade fair in Kapellen, Belgium in November 1999. Five cases died. Epidemiological investigation showed

Cite
De Schrijver K, Van Bouwel E, Mortelmans L, et al. An outbreak of legionnaire s disease among visitors to a fair in Belgium, 1999. Euro Surveill. 2000;5(11):115-119doi: 10.2807/esm.05.11.00007-en.
De Schrijver, K., Van Bouwel, E., Mortelmans, L., Van Rossom, P., De Beukelaer, T., Vael, C., Dirven, K., Goossens, H., Leven, M., & Ronveaux, O. (2000). An outbreak of legionnaire s disease among visitors to a fair in Belgium, 1999. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 5(11), 115-119. https://doi.org/10.2807/esm.05.11.00007-en
De Schrijver, K, et al. "An outbreak of legionnaire s disease among visitors to a fair in Belgium, 1999." Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin vol. 5,11 (2000): 115-119. doi: https://doi.org/10.2807/esm.05.11.00007-en
De Schrijver K, Van Bouwel E, Mortelmans L, Van Rossom P, De Beukelaer T, Vael C, Dirven K, Goossens H, Leven M, Ronveaux O. An outbreak of legionnaire s disease among visitors to a fair in Belgium, 1999. Euro Surveill. 2000 Nov;5(11):115-119. doi: 10.2807/esm.05.11.00007-en. PMID: 12631961.
Copy Download .nbib Format: NLM
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.

Frontiers in pharmacology

Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J.
PMID: 32719607
Front Pharmacol. 2020 Jul 03;11:1007. doi: 10.3389/fphar.2020.01007. eCollection 2020.

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, increase the risk...

Cite
Haguet H, Bouvy C, Delvigne AS, et al. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020;11:1007doi: 10.3389/fphar.2020.01007.
Haguet, H., Bouvy, C., Delvigne, A. S., Modaffari, E., Wannez, A., Sonveaux, P., Dogné, J. M., & Douxfils, J. (2020). The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Frontiers in pharmacology, 111007. https://doi.org/10.3389/fphar.2020.01007
Haguet, Hélène, et al. "The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study." Frontiers in pharmacology vol. 11 (2020): 1007. doi: https://doi.org/10.3389/fphar.2020.01007
Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020 Jul 03;11:1007. doi: 10.3389/fphar.2020.01007. eCollection 2020. PMID: 32719607; PMCID: PMC7350860.
Copy Download .nbib Format: NLM
Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells.

Frontiers in pharmacology

Grasso D, Medeiros HCD, Zampieri LX, Bol V, Danhier P, van Gisbergen MW, Bouzin C, Brusa D, Grégoire V, Smeets H, Stassen APM, Dubois LJ, Lambin P, Dutreix M, Sonveaux P.
PMID: 32231567
Front Pharmacol. 2020 Mar 13;11:263. doi: 10.3389/fphar.2020.00263. eCollection 2020.

The clinical management of head and neck squamous cell carcinoma (HNSCC) commonly involves chemoradiotherapy, but recurrences often occur that are associated with radioresistance. Using human SQD9 laryngeal squamous cell carcinoma cancer cells as a model, we aimed to identify...

Cite
Grasso D, Medeiros HCD, Zampieri LX, et al. Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Front Pharmacol. 2020;11:263doi: 10.3389/fphar.2020.00263.
Grasso, D., Medeiros, H. C. D., Zampieri, L. X., Bol, V., Danhier, P., van Gisbergen, M. W., Bouzin, C., Brusa, D., Grégoire, V., Smeets, H., Stassen, A. P. M., Dubois, L. J., Lambin, P., Dutreix, M., & Sonveaux, P. (2020). Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Frontiers in pharmacology, 11263. https://doi.org/10.3389/fphar.2020.00263
Grasso, Debora, et al. "Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells." Frontiers in pharmacology vol. 11 (2020): 263. doi: https://doi.org/10.3389/fphar.2020.00263
Grasso D, Medeiros HCD, Zampieri LX, Bol V, Danhier P, van Gisbergen MW, Bouzin C, Brusa D, Grégoire V, Smeets H, Stassen APM, Dubois LJ, Lambin P, Dutreix M, Sonveaux P. Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Front Pharmacol. 2020 Mar 13;11:263. doi: 10.3389/fphar.2020.00263. eCollection 2020. PMID: 32231567; PMCID: PMC7082361.
Copy Download .nbib Format: NLM
Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer.

Frontiers in oncology

Avnet S, Baldini N, Brisson L, Pedersen SF, Porporato PE, Sonveaux P, Szabadkai G, Pastorekova S.
PMID: 31850217
Front Oncol. 2019 Nov 28;9:1332. doi: 10.3389/fonc.2019.01332. eCollection 2019.

The metabolism of cancer cells differs from that of their normal counterparts in a spectrum of attributes, including imbalances in diverse metabolic arms and pathways, metabolic plasticity and extent of adaptive responses, levels, and activities of metabolic enzymes and...

Cite
Avnet S, Baldini N, Brisson L, et al. Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer. Front Oncol. 2019;9:1332doi: 10.3389/fonc.2019.01332.
Avnet, S., Baldini, N., Brisson, L., Pedersen, S. F., Porporato, P. E., Sonveaux, P., Szabadkai, G., & Pastorekova, S. (2019). Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer. Frontiers in oncology, 91332. https://doi.org/10.3389/fonc.2019.01332
Avnet, Sofia, et al. "Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer." Frontiers in oncology vol. 9 (2019): 1332. doi: https://doi.org/10.3389/fonc.2019.01332
Avnet S, Baldini N, Brisson L, Pedersen SF, Porporato PE, Sonveaux P, Szabadkai G, Pastorekova S. Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer. Front Oncol. 2019 Nov 28;9:1332. doi: 10.3389/fonc.2019.01332. eCollection 2019. PMID: 31850217; PMCID: PMC6892776.
Copy Download .nbib Format: NLM
Tetrasomy 15q11-q13 diagnosed by FISH in a patient with autistic disorder.

Journal of biomedicine & biotechnology

Ouldim K, Natiq A, Jonveaux P, Sefiani A.
PMID: 17541469
J Biomed Biotechnol. 2007;2007(3):61538. doi: 10.1155/2007/61538. Epub 2007 Mar 20.

We report the case of a Moroccan boy with mental retardation, hyperactivity, epilepsy, developmental problems and behavioural disorders. Cytogenetic analysis showed the presence of a supernumerary marker chromosome. Molecular cytogenetics allowed us to determine the marker as an inverted...

Cite
Ouldim K, Natiq A, Jonveaux P, et al. Tetrasomy 15q11-q13 diagnosed by FISH in a patient with autistic disorder. J Biomed Biotechnol. 2007;2007(3):61538doi: 10.1155/2007/61538.
Ouldim, K., Natiq, A., Jonveaux, P., & Sefiani, A. (2007). Tetrasomy 15q11-q13 diagnosed by FISH in a patient with autistic disorder. Journal of biomedicine & biotechnology, 2007(3), 61538. https://doi.org/10.1155/2007/61538
Ouldim, Karim, et al. "Tetrasomy 15q11-q13 diagnosed by FISH in a patient with autistic disorder." Journal of biomedicine & biotechnology vol. 2007,3 (2007): 61538. doi: https://doi.org/10.1155/2007/61538
Ouldim K, Natiq A, Jonveaux P, Sefiani A. Tetrasomy 15q11-q13 diagnosed by FISH in a patient with autistic disorder. J Biomed Biotechnol. 2007;2007(3):61538. doi: 10.1155/2007/61538. Epub 2007 Mar 20. PMID: 17541469; PMCID: PMC1874673.
Copy Download .nbib Format: NLM
Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide.

Molecular & cellular oncology

Porporato PE, Sonveaux P.
PMID: 27308448
Mol Cell Oncol. 2014 Oct 29;2(3):e968043. doi: 10.4161/23723548.2014.968043. eCollection 2015.

Metastatic dissemination is associated with poor prognosis of cancer patients. While exploring glucose metabolism in metastatic progenitor cells, we recently found that several different dysfunctions that share the ability to induce mitochondrial superoxide production also promote tumor metastasis. Selective...

Cite
Porporato PE, Sonveaux P. Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide. Mol Cell Oncol. 2014;2(3):e968043doi: 10.4161/23723548.2014.968043.
Porporato, P. E., & Sonveaux, P. (2015). Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide. Molecular & cellular oncology, 2(3), e968043. https://doi.org/10.4161/23723548.2014.968043
Porporato, Paolo E, and Sonveaux, Pierre. "Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide." Molecular & cellular oncology vol. 2,3 (2015): e968043. doi: https://doi.org/10.4161/23723548.2014.968043
Porporato PE, Sonveaux P. Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide. Mol Cell Oncol. 2014 Oct 29;2(3):e968043. doi: 10.4161/23723548.2014.968043. eCollection 2015. PMID: 27308448; PMCID: PMC4905283.
Copy Download .nbib Format: NLM
Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis.

Biomaterials

Gouel F, Timmerman K, Gosset P, Raoul C, Dutheil M, Jonneaux A, Garçon G, Moreau C, Danel-Brunaud V, Duce J, Burnouf T, Devedjian JC, Devos D.
PMID: 34952382
Biomaterials. 2021 Dec 04;280:121311. doi: 10.1016/j.biomaterials.2021.121311. Epub 2021 Dec 04.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease of motor neurons leading to death within 3 years and without a curative treatment. Neurotrophic growth factors (NTFs) are pivotal for cell survival. A reason for the lack of patient...

Cite
Gouel F, Timmerman K, Gosset P, et al. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials. 2021;280:121311doi: 10.1016/j.biomaterials.2021.121311.
Gouel, F., Timmerman, K., Gosset, P., Raoul, C., Dutheil, M., Jonneaux, A., Garçon, G., Moreau, C., Danel-Brunaud, V., Duce, J., Burnouf, T., Devedjian, J. C., & Devos, D. (2021). Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials, 280121311. https://doi.org/10.1016/j.biomaterials.2021.121311
Gouel, Flore, et al. "Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis." Biomaterials vol. 280 (2021): 121311. doi: https://doi.org/10.1016/j.biomaterials.2021.121311
Gouel F, Timmerman K, Gosset P, Raoul C, Dutheil M, Jonneaux A, Garçon G, Moreau C, Danel-Brunaud V, Duce J, Burnouf T, Devedjian JC, Devos D. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials. 2021 Dec 04;280:121311. doi: 10.1016/j.biomaterials.2021.121311. Epub 2021 Dec 04. PMID: 34952382.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries